CAMP4 (Nasdaq: CAMP) granted non-qualified stock options totaling 43,000 shares on April 15, 2026 as inducement awards to three newly hired employees under Nasdaq Rule 5635(c)(4).
The options have a 10-year term, an exercise price of $4.59 per share (closing price on the grant date) and vest over four years (25% at one year, then monthly over 36 months).
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – CAMP
+0.45%
1 alert
+0.45%Session close to close
$249.21MMarket Cap
0.1xRel. Volume
In the Apr 20 session, CAMP gained 0.45%, reflecting a mild positive market reaction.
This announcement details routine inducement stock option grants totaling 43,000 shares at an exerci...
Analysis
This announcement details routine inducement stock option grants totaling 43,000 shares at an exercise price of $4.59, aligning with Nasdaq Listing Rule 5635(c)(4). It follows months of active corporate developments, including GSK collaboration funding of $17.5M upfront and cash of $109.5M as of year-end 2025. Investors may watch how ongoing use of the $300M S-3 shelf and $100M ATM, plus pipeline milestones, interact with these equity-based compensation grants.
Key Figures
Inducement options:43,000 sharesExercise price:$4.59 per shareOption term:10 years+5 more
8 metrics
Inducement options43,000 sharesNon-qualified stock options granted to three new employees on April 15, 2026
Exercise price$4.59 per shareEqual to CAMP4 closing price on April 15, 2026 (Grant Date)
Option term10 yearsTerm of each inducement stock option grant
Vesting schedule4 years25% at first anniversary, remainder in 36 equal monthly installments
New employees3 employeesRecipients of inducement grants under Nasdaq Listing Rule 5635(c)(4)
Grant DateApril 15, 2026Date Compensation Committee approved the inducement grants
Current price$4.50Pre-news trading level from market context
52-week range$1.305 – $7.7552-week low and high prior to this announcement
Announced 8,000-share option grant to a new employee with four-year vesting.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent history shows multiple instances where seemingly constructive corporate or financing updates were followed by negative price reactions, alongside very strong moves around conference participation.
Recent Company History
Over the last few months, CAMP has reported full-year 2025 results with substantial cash of $109.5M, a major GSK collaboration, and equity financings, yet the stock fell 8.5% the next day. Board and management developments, including appointing Michael MacLean and expanding the board, also saw a -3.41% move. By contrast, simple conference-participation news on March 6, 2026 coincided with a sharp 49.4% gain. Prior inducement grants in January and February produced mixed reactions, underscoring inconsistent trading responses to routine corporate updates.
"granted non-qualified stock options ... in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
non-qualified stock optionsfinancial
"granted non-qualified stock options to purchase an aggregate of 43,000 shares"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
exercise pricefinancial
"an exercise price per share of $4.59, which is equal to the closing price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestingfinancial
"The Inducement Grants will vest over a four-year period, with 25% of the shares vesting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
inducement grantsregulatory
"each as an inducement material to such employee’s entry into employment"
Inducement grants are special awards of shares or stock options given to new employees to encourage them to join a company or accept a new role. They act like a welcome bonus, providing an extra incentive to attract talent. For investors, these grants can impact a company's costs and share structure, influencing the value of their investments.
inducement option award agreementregulatory
"subject to, the terms and conditions of an Inducement Option Award Agreement"
An inducement option award agreement is a contract that gives a new employee or executive the right to buy company shares at a set price as a hiring incentive, similar to a signing bonus paid in stock rather than cash. Investors care because these awards can increase the number of shares outstanding (dilution), create future expense on the company’s books, and signal how management is being rewarded and motivated to grow the business.
CAMBRIDGE, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on April 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 43,000 shares of the Company’s common stock to three newly hired employees of the Company, each as an inducement material to such employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grants”).
The Inducement Grants each have a ten-year term and an exercise price per share of $4.59, which is equal to the closing price of CAMP4’s common stock as of the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s first day of employment with the Company, and thereafter the remainder of the option will vest in 36 equal monthly installments, subject to the employee’s continued service with CAMP4 through the applicable vesting dates. Each Inducement Grant was granted pursuant to, and is subject to, the terms and conditions of an Inducement Option Award Agreement.
About CAMP4 Therapeutics CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.
What did CAMP4 (CAMP) announce on April 15, 2026 about inducement grants?
CAMP4 granted inducement stock options covering 43,000 shares to three new hires on April 15, 2026. According to CAMP4, the options have a 10-year term, exercise price of $4.59, and standard four-year vesting.
How does the vesting schedule work for CAMP4's April 15, 2026 inducement options (CAMP)?
The options vest over four years with 25% at one year and the remainder monthly over 36 months. According to CAMP4, vesting is conditioned on continued service through each vesting date.
What is the exercise price and term for CAMP4 inducement grants reported April 17, 2026?
The inducement options carry an exercise price of $4.59 per share and a 10-year term. According to CAMP4, $4.59 equals the closing price of CAMP4 common stock on the grant date.
Who received the inducement grants in CAMP4's April 2026 announcement and why does it matter to investors?
Three newly hired employees received the grants as inducements to join CAMP4. According to CAMP4, such awards are used to recruit key talent and align employee incentives with shareholder interests.
Are CAMP4's inducement option awards subject to any agreement or conditions (CAMP)?
Yes, each inducement grant is governed by an Inducement Option Award Agreement. According to CAMP4, the awards are subject to the agreement terms and continued employee service for vesting.
